1
|
Casanova MJ, Nantes Ó, Varela P, Vela-González M, Rivero M, Sierra-Gabarda O, Riestra S, Acosta MBD, Del Mar Martín-Rodríguez M, Gargallo-Puyuelo CJ, Reygosa C, Muñoz R, de la Filia-Molina IG, Núñez-Ortiz A, Kolle L, Calafat M, Huguet JM, Iglesias-Flores E, Martínez-Pérez TDJ, Bosch O, Duque-Alcorta JM, Frago-Larramona S, Van Domselaar M, González-Cosano VM, Bujanda L, Rubio S, Mancebo A, Castro B, García-López S, de Francisco R, Nieto-García L, Laredo V, Gutiérrez-Casbas A, Mesonero F, Leo-Carnerero E, Cañete F, Ruiz L, Gros B, Del Moral-Martínez M, Rodríguez C, Chaparro M, Gisbert JP. Real-world outcomes of switching from adalimumab originator to adalimumab biosimilar in patients with inflammatory bowel disease: The ADA-SWITCH study. Aliment Pharmacol Ther 2023. [PMID: 37089065 DOI: 10.1111/apt.17525] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/07/2023] [Revised: 02/18/2023] [Accepted: 04/06/2023] [Indexed: 04/25/2023]
Abstract
BACKGROUND AND AIMS Data on the outcomes after switching from adalimumab (ADA) originator to ADA biosimilar are limited. The aim was to compare the treatment persistence, clinical efficacy, and safety outcomes in inflammatory bowel disease patients who maintained ADA originator vs. those who switched to ADA biosimilar. METHODS Patients receiving ADA originator who were in clinical remission at standard dose of ADA originator were included. Patients who maintained ADA originator formed the non-switch cohort (NSC), and those who switched to different ADA biosimilars constituted the switch cohort (SC). Clinical remission was defined as a Harvey-Bradshaw index ≤4 in Crohn's disease and a partial Mayo score ≤2 in ulcerative colitis. To control possible confounding effects on treatment discontinuation, an inverse probability treatment weighted proportional hazard Cox regression was performed. RESULTS Five hundred and twenty-four patients were included: 211 in the SC and 313 in the NSC. The median follow-up was 13 months in the SC and 24 months in the NSC (p < 0.001). The incidence rate of ADA discontinuation was 8% and 7% per patient-year in the SC and in the NSC, respectively (p > 0.05). In the multivariate analysis, switching from ADA originator to ADA biosimilar was not associated with therapy discontinuation. The incidence rate of relapse was 8% per patient-year in the SC and 6% per patient-year in the NSC (p > 0.05). Six percent of the patients had adverse events in the SC vs. 5% in the NSC (p > 0.05). CONCLUSION Switching to ADA biosimilar did not impair patients' outcomes in comparison with maintaining on the originator.
Collapse
Affiliation(s)
- María José Casanova
- Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | - Óscar Nantes
- Gastroenterology Department, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - Pilar Varela
- Gastroenterology Department, Hospital Universitario de Cabueñes, Gijón, Spain
| | - Milagros Vela-González
- Gastroenterology Department, Hospital Universitario Nuestra Señora de la Candelaria, Santa Cruz de Tenerife, Spain
| | - Montserrat Rivero
- Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain
| | | | - Sabino Riestra
- Gastroenterology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Manuel Barreiro-de Acosta
- Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | | | - Carla Jerusalén Gargallo-Puyuelo
- Gastroenterology Department, Hospital Clínico Lozano Blesa, Instituto de Investigación Sanitaria Aragón (IIS Aragón), y CIBEREHD, Zaragoza, Spain
| | - Cristina Reygosa
- Gastroenterology Department, Hospital Universitario de Canarias, La Laguna, Spain
| | - Roser Muñoz
- Gastroenterology Department, Hospital General Universitario Dr. Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), y CIBEREHD, Alicante, Spain
| | | | - Andrea Núñez-Ortiz
- Gastroenterology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Lilyan Kolle
- Gastroenterology Department, Hospital General de La Palma, Santa Cruz de Tenerife, Spain
| | - Margalida Calafat
- Gastroenterology Department, Hospital Universitario Germans Trias i Pujol, y CIBEREHD, Badalona, Spain
| | - José María Huguet
- Gastroenterology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
| | - Eva Iglesias-Flores
- Gastroenterology Department, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
| | | | - Orencio Bosch
- Gastroenterology Department, Fundación Jiménez Díaz, Madrid, Spain
| | | | | | | | | | - Luis Bujanda
- Gastroenterology Department, Hospital Universitario de Donostia, Instituto Biodonostia, Universidad del País Vasco (UPV/EHU), y CIBEREHD, Donostia, Spain
| | - Saioa Rubio
- Gastroenterology Department, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - Alejo Mancebo
- Gastroenterology Department, Hospital Universitario de Cabueñes, Gijón, Spain
| | - Beatriz Castro
- Gastroenterology Department, Hospital Universitario Marqués de Valdecilla, Instituto de Investigación Sanitaria Valdecilla (IDIVAL), Santander, Spain
| | | | - Ruth de Francisco
- Gastroenterology Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
| | - Laura Nieto-García
- Gastroenterology Department, Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | - Viviana Laredo
- Gastroenterology Department, Hospital Clínico Lozano Blesa, Instituto de Investigación Sanitaria Aragón (IIS Aragón), y CIBEREHD, Zaragoza, Spain
| | - Ana Gutiérrez-Casbas
- Gastroenterology Department, Hospital General Universitario Dr. Balmis, Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), y CIBEREHD, Alicante, Spain
| | - Francisco Mesonero
- Gastroenterology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | - Eduardo Leo-Carnerero
- Gastroenterology Department, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - Fiorella Cañete
- Gastroenterology Department, Hospital Universitario Germans Trias i Pujol, y CIBEREHD, Badalona, Spain
| | - Lucía Ruiz
- Gastroenterology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain
| | - Beatriz Gros
- Gastroenterology Department, Hospital Universitario Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Córdoba, Spain
| | | | - Cristina Rodríguez
- Gastroenterology Department, Hospital Universitario de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - María Chaparro
- Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| | - Javier P Gisbert
- Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain
| |
Collapse
|